In October 2026, the Canadian Life and Health Insurance Association released its annual fact book, reporting C$157 billion in life, health and retirement benefits paid in 2025, a 10% increase. The release was published on 20 October. For employer benefits buyers, the figures provide context for the Canadian market, but their broad scope makes them unsuitable as a direct estimate of the renewal increase an individual medical plan should expect.

Keep the scope of the aggregate visible

The association also reports more than C$18 billion in prescription-drug coverage and nearly C$1.1 billion in mental-health support. The latter rose 160% over five years. These amounts describe payments across an industry and over specified periods. They do not identify how much of a particular employer’s change arose from negotiated prices, more people covered, increased use or a change in the benefits available.

An employer dashboard should retain the reporting period and the population attached to each number. Comparing an annual industry total with a plan’s paid claims requires attention to the benefits included, the treatment of dependants and the timing of payments. A percentage that appears consistent with a renewal quote can still describe a different underlying measure. The comparison should explain those differences before drawing a conclusion.

Separate price changes from access and use

Higher payments can reflect several developments with different implications for a sponsor. More use of an existing service may indicate that employees can finally access care. Higher unit prices may create a purchasing issue. Adding a benefit may increase spending while improving protection. A combined total cannot resolve those possibilities. Employers need a claims analysis that follows the same definitions across the periods being compared.

Mental-health provision illustrates the problem. A rise in reimbursements alone does not show whether waiting times improved or whether employees received suitable treatment. A review could examine the number of people using the benefit, the services paid for and any access problems reported through appropriately aggregated channels. It should avoid identifying individuals or allowing sensitive health information to become an employment-management tool.

Use drug spending to frame a purchasing discussion

For medicines, the practical question is which parts of the employer’s own experience can be explained. Buyers could ask the administrator to separate changes in the covered population from changes in cost per treated person. They could then examine significant categories with the relevant clinical and pharmacy expertise. National spending is a reason to ask better questions, rather than evidence that every drug-management intervention will save money.

Any proposed change should be assessed for its effect on access as well as the budget. A lower reimbursement limit may reduce plan payments by shifting costs to employees. That financial result differs from obtaining an equivalent treatment at a lower price. The business case should state whose costs are counted and consider the practical consequences for continuity of treatment before describing the change as an efficiency.

Translate national figures into multinational reporting

Headquarters comparing countries should retain Canadian currency and the original benefit categories before converting results into a group reporting currency. Exchange-rate movements should be shown separately from local claims changes. An apparently large movement in a consolidated dashboard may otherwise obscure what happened in the underlying programme. These are reporting controls for the employer to adopt, not conclusions established by the CLHIA figures.

For captive or pooling reviews, the same discipline applies to the population and period actually financed. An industry aggregate cannot stand in for the insured contracts, claims and expenses within that arrangement. Independent non-executive directors should challenge mismatched comparisons and ask management to explain the bridge from local experience to any proposed financing decision.

The fact book is a useful starting point for a Canadian market briefing. The next analytical step is a consistent plan-level comparison that separates the drivers of spending and records what remains uncertain. That gives benefits committees a basis for discussing access and affordability without mistaking a national payout total for a medical-inflation forecast.

Sources

CLHIA fact book released: 20 October 2026. Underlying reporting year: 2025. Canadian insurers report C$157 billion in life, health and retirement benefits